Sort   by:  
 Page size 
ProteomicsHLA class I MAPPs Assay in 10 mono-allelic cell lines transfected with SaCas9, AsCas12a and CasΦ
MHC-associated peptide proteomics (MAPPs) enables direct identification of intracellular peptides naturally processed and presented by cells, providing experimental evidence for antigen processing and HLA class I presentation. In this dataset an HLA-A/B/C-focused MAPPs workflow was used on 10 mono-a...
ORGANISM(S): Homo sapiens (Human) 
2026-09-14 | PXD073207 | Pride
GenomicsRandomized PAM depletion of AsCas12a
Randomized PAM depletion of AsCas12a
PRJNA508763 | ENA
OtherRandomized PAM depletion of AsCas12a
We report the PAMs of AsCas12a using a cell-free TXTL-based cleavage assay. By adding randomized PAM library and AsCas12a-gRNA in vitro, functional PAM sequences were cleaved, while non-functional PAMs remained. By amplifying the non-cleaved DNA, we use next-generation sequencing to analyze the depl...
ORGANISM(S): synthetic construct 
2019-01-01 | GSE123443 | GEO
UnknownAsCas12a tolerates insertions in target DNA.
Not available
S-EPMC12448901 | biostudies-literature
UnknownAsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines.
Not available
S-EPMC8222333 | biostudies-literature
Genomics
AsCas12a Ultra manuscript
PRJNA730915 | ENA
UnknownEfficient Genome Editing Using 'NanoMEDIC' AsCas12a-VLPs Produced with Pol II-Transcribed crRNA.
Not available
S-EPMC11641575 | biostudies-literature
ProteomicsRational engineering of minimally immunogenic nucleases for gene therapy
Genome editing using CRISPR-Cas systems is a promising avenue for the treatment of genetic diseases. However, cellular and humoral immunogenicity of genome editing tools, which originate from bacteria, complicates their clinical use. Here we report reduced immunogenicity (Red)(i)-variants of two cli...
ORGANISM(S): Homo sapiens (Human) 
2024-11-07 | PXD054579 | Pride
Sacas9 Mapps Ascas12a Gene therapy 
Genomics
AsCas12a editing in endogenous gene
PRJNA799943 | ENA
UnknownCRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in Induced Pluripotent Stem Cells from an Ocular Albinism Patient.
Not available
S-EPMC9233509 | biostudies-literature
Sort   by:  
 Page size